NHLRC1

Chr 6AR

NHL repeat containing E3 ubiquitin protein ligase 1

Also known as: EPM2B, MALIN, MELF2, bA204B7.2

This gene encodes an E3 ubiquitin-protein ligase that works with laforin phosphatase to clear toxic polyglucosan and protein aggregates through both the ubiquitin-proteasome system and autophagy pathways. Biallelic mutations cause Lafora disease (progressive myoclonic epilepsy type 2), a devastating autosomal recessive neurodegenerative disorder typically presenting in adolescence with progressive myoclonic epilepsy and cognitive decline.

GeneReviewsOMIMResearchSummary from RefSeq, OMIM, UniProt
MultiplemechanismARLOEUF 0.881 OMIM phenotype
Clinical SummaryNHLRC1
🧬
Gene-Disease Validity (ClinGen)
Lafora disease · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.34) despite low pLI — interpret in context.
📖
GeneReview available — NHLRC1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.88LOEUF
pLI 0.094
Z-score 1.82
OE 0.34 (0.150.88)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.50Z-score
OE missense 0.91 (0.811.02)
219 obs / 240.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.34 (0.150.88)
00.351.4
Missense OE0.91 (0.811.02)
00.61.4
Synonymous OE1.04
01.21.6
LoF obs/exp: 3 / 8.8Missense obs/exp: 219 / 240.6Syn Z: -0.34
DN
0.6455th %ile
GOF
0.6637th %ile
LOF
0.3649th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

NHLRC1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →